Clinical trials: Chronic Obstructive Pulmonary Disease, Unspecified
- Condition Chronic Obstructive Pulmonary Disease, Unspecified
- Funder type Industry (pharma, biotech, devices)
Respiratory Disorders
A Study to Assess Immunity to Specific Microbial Antigens in Healthy Smokers and Non-smokers and in Subjects With Stable COPD
The present study aims to assess the natural immunity to specific microbial antigens in healthy subjects and in subjects with stable COPD aged between 45-75 years.
- Trial name
- NCT01516437
- Testing
- Blood collection, Swab collection, Sputum collection
- Where
- 3 sites in Belgium
- Volunteers
- 73 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease
Study of Fluticasone/Formoterol/Glycopyrronium for the Treatment Chronic Obstructive Pulmonary Disease (TRIPLAR)
Several studies have demonstrated the benefits of the LAMA (Long-Acting Muscarinic Antagonists) + LABA (Long-Acting Beta-Agonists) + IC (inhaled corticosteroids) combination in the treatment of chronic obstructive pulmonary…
- Trial name
- TRIPLAR (NCT06234345)
- Testing
- Fluticasone 250mcg/Formoterol 12mcg/Glycopyrronium 25mcg, Comparator - Trimbow®
- Where
- Brazil
- Volunteers
- 1,252 people
- Sponsor
- Eurofarma Laboratorios S.A.
Emphysema or COPD, Emphysema
The REDUCE EU Study - Endobronchial Thermal Liquid Ablation (ETLA) for the Treatment of Emphysema
The goal of this clinical trial is to learn if bronchoscopic lung volume reduction with endobronchial thermal liquid ablation (ETLA) works to treat severe emphysema in terms of feasibility and safety.
- Conditions
- Emphysema or COPD, Emphysema, Emphysema, Pulmonary, COPD
- Trial name
- NCT06655428
- Testing
- Endobronchial Therman Liquid Ablation (ETLA)
- Where
- 7 sites in Austria, Germany and 1 more
- Volunteers
- 30 people
- Sponsor
- Morair Medtech, LLC
Pulmonary Hypertension
Frespaciguat (MK-5475) in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD) (MK-5475-006)
The primary objectives of this study are to assess the safety/tolerability and efficacy (by evaluating changes in pulmonary vascular resistance [PVR] and pulmonary blood volume [PBV]) of frespaciguat in participants with…
- Trial name
- NCT04370873
- Testing
- Frespaciguat
- Where
- 9 sites in United States, Israel and 1 more
- Volunteers
- 22 people
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Obstructive Pulmonary Disease
A Clinical Trial of TQC3721 Suspension for Inhalation
To evaluate the safety, tolerability and pharmacokinetic characteristics of TQC3721 suspension for inhalation in single/multiple administration(s) in healthy subjects; to evaluate the safety,tolerability and efficacy TQC3721…
- Trial name
- NCT05051930
- Testing
- TQC3721 suspension for inhalation
- Where
- China
- Volunteers
- 114 people, healthy volunteers welcome
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Chronic Obstructive Pulmonary Disease
Relative Bioavailability Study With Abediterol Administered Via Three Different Inhalation Devices in Healthy Volunteers.
The study is intended to assess the relative bioavailability of 2 different abediterol nebulised formulations (test) and the dry powder formulation (reference).
- Trial name
- NCT04199598
- Testing
- Abediterol (2.4 μg), Abediterol (4.8 μg), Abediterol (2.5 μg)
- Where
- Germany
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
Tiotropium/Salmeterol Inhalation Powder in COPD
The primary objectives of this study are to assess bronchodilator efficacy as determined by forced expiratory volume in one second (FEV1), the effect on dyspnoea as determined by the Baseline Dyspnoea Index (BDI)/Transition…
- Trial name
- NCT00668772
- Testing
- Tiotropium/Salmeterol, Salmeterol, Tiotropium
- Where
- 64 sites in United States, Austria and 15 more
- Volunteers
- 207 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease
Efficacy and Safety Study of PT009, PT008, and PT005 in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
This is a Phase IIb, randomized, double blind, chronic dosing (28 days), four period, five treatment, incomplete block, crossover design in subjects with moderate to severe COPD.
- Trial name
- PT009001 (NCT02196077)
- Testing
- BFF MDI 320/9.6 μg, BFF MDI 160/9.6 μg, BFF MDI 80/9.6 μg
- Where
- 17 sites in United States
- Volunteers
- 180 people
- Sponsor
- Pearl Therapeutics, Inc.
Chronic Obstructive Pulmonary Disease
Foster® pMDI (CHF 1535) Versus Symbicort® Turbohaler in COPD Patient (FORSYYN)
Primary Objective To demonstrate that CHF 1535 pMDI is non-inferior to Symbicort® Turbohaler® in terms of pulmonary function (change from baseline in pre-dose morning FEV1 at Week 24) in patients with COPD.
- Trial name
- FORSYYN (NCT03888131)
- Where
- 53 sites in China
- Volunteers
- 750 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Chronic Obstructive Pulmonary Disease
A Study in Patients With Chronic Obstructive Pulmonary Disease (FAIR)
The purpose of the present study is to demonstrate the higher efficacy of small particles Foster® 100/6 (two puffs b.i.d.) versus large particles Symbicort® 200/6 (two inhalations b.i.d.), in terms of residual volume reduction…
- Trial name
- FAIR (NCT01351792)
- Testing
- Foster® 100/6 µg/unit dose, Symbicort® Turbohaler® 200/6 μg/actuation
- Where
- Netherlands
- Volunteers
- 113 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Asthma, Pulmonary Disease, Chronic Obstructive
A Study for Disease Profiling of Asthma and Chronic Obstructive Pulmonary Disease
The purpose of this study is to characterize the clinical, physiologic, and molecular profiles of healthy participants, participants with mild, moderate, and severe asthma; and participants with moderate to severe Chronic…
- Trial name
- NCT01274507
- Testing
- Medical tests
- Where
- 21 sites in United States, Canada and 6 more
- Volunteers
- 328 people
- Sponsor
- Janssen Research & Development, LLC
Chronic Obstructive Pulmonary Disease
A 52-week, Placebo-controlled Study to Evaluate the Efficacy and Safety of 2 Doses of CHF6001 DPI (Tanimilast), as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis (PILASTER)
The purpose of the study is to evaluate the efficacy and safety of two doses of CHF6001 (Tanimilast), as add-on to maintenance triple therapy in the target patient population.
- Trial name
- PILASTER (NCT04636801)
- Testing
- Experimental: CHF6001 1600µg, Experimental: CHF6001 3200µg
- Where
- 447 sites in United States, Albania and 28 more
- Volunteers
- 4,710 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Chronic Obstructive Pulmonary Disease
An Efficacy Study of BCS Clearing the Oral Colonized Bacterium in Hospitalized Patients With COPD
The purpose of study is to evaluate the efficacy and safety of Benzalkonium Chloride Solution clearing the oral colonized bacterium in hospitalized patients with COPD.
- Trial name
- NCT02269800
- Testing
- Benzalkonium chloride solution, Normal saline
- Volunteers
- 60 people
- Sponsor
- Lustre Pharmaceutical Lab Co., Ltd
Pulmonary Disease, Chronic Obstructive
Efficacy of Tiotropium in Patients of African Descent With Chronic Obstructive Pulmonary Disease
The purpose of this study is to look at the benefits of tiotropium, an approved drug for the treatment of bronchospasm associated with COPD (chronic obstructive pulmonary disease), in a population of patients with COPD who are of…
- Trial name
- NCT00106821
- Testing
- Tiotropium Bromide Inhalation Powder
- Where
- 19 sites in United States
- Volunteers
- 166 people
- Sponsor
- Boehringer Ingelheim
Heart Failure, Chronic Obstructive Pulmonary Disease
Coventry Outcomes Study of Seniors (COSS): A Comparative Effectiveness Study to Evaluate the Effect of a Multidisciplinary Team's Intervention on the Incidence of Nonelective Hospitalizations in a Medicare Population
The investigators are studying the impact of the interventions of a multidisciplinary team (MDT) - consisting of a Coventry case manager, social worker, and medical director, alongside a Medco specialist pharmacist - on the…
- Conditions
- Heart Failure, Chronic Obstructive Pulmonary Disease, Cardiovascular Disease, Diabetes
- Trial name
- COSS (NCT01014884)
- Testing
- Multidisciplinary team interventions, Multidisciplinary team bimonthly visits either in person or via telephone., Usual case management and pharmacy management as provided by the health Plan and the pharmacy benefit manager
- Where
- 2 sites in United States
- Volunteers
- 2,150 people
- Sponsor
- Medco Health Solutions, Inc.
Chronic Obstructive Pulmonary Disease
A Study of TQC3927 Powder for Inhalation in Healthy Adult Subjects
This is a dose escalation trial. The dosing regimen involves a single-dose study. This is a single-center, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability and pharmacokinetic…
- Trial name
- NCT06408285
- Testing
- TQC3927 powder for inhalation
- Where
- China
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Pulmonary Disease, Chronic Obstructive
A Study to Evaluate the Effectiveness and Safety of CNTO6785 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
The purpose of the study is to evaluate the effect of CNTO6785 compared with placebo in participants with moderate to severe Chronic Obstructive Pulmonary Disease.
- Trial name
- NCT01966549
- Testing
- CNTO 6785
- Where
- 44 sites in Czechia, Germany and 6 more
- Volunteers
- 187 people
- Sponsor
- Janssen Research & Development, LLC
Pulmonary Disease, Chronic Obstructive
A Study to Evaluate the Effectiveness of MEDI-563 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
To evaluate the effect of the drug in moderate to severe Chronic Obstructive Pulmonary Disease (COPD) in Adults.
- Trial name
- NCT01227278
- Testing
- Benralizumab 100 mg
- Where
- 31 sites in United States, Canada and 5 more
- Volunteers
- 421 people
- Sponsor
- MedImmune LLC
Pulmonary Disease, Chronic Obstructive
Study to Evaluate Efficacy and Safety of Mepolizumab for Frequently Exacerbating Chronic Obstructive Pulmonary Disease (COPD) Patients
This is a multi-center, randomized, placebo-controlled, double-blind, parallel group trial evaluating mepolizumab 100 mg against placebo given every 4 weeks through subcutaneous (SC) injection.
- Trial name
- NCT02105948
- Testing
- Mepolizumab
- Where
- 116 sites in United States, Australia and 14 more
- Volunteers
- 837 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease
A Study to Evaluate the Efficacy of MEDI8968 in Chronic Obstructive Pulmonary Disease
The purpose of this study is to evaluate the effect of MEDI8968 on the rate of moderate or severe acute exacerbations of chronic obstructive pulmonary disease (AECOPD) in adult subjects with symptomatic, moderate to very severe…
- Trial name
- SPRING (NCT01448850)
- Testing
- MEDI8968 600 mg IV, 300 mg SC
- Where
- 60 sites in United States, Bulgaria and 8 more
- Volunteers
- 464 people
- Sponsor
- MedImmune LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.